Global Synagis Market Expected To Reach $113.35 Billion By 2030 With 7.6% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

By 2030, What Market Size Is The Synagis Market Expected To Reach Based On Its 2026 Value?

The historical period’s growth stemmed from a heightened occurrence of RSV infections among infants, an escalating understanding of preventative monoclonal treatments, the broader availability of neonatal intensive care facilities, the provision of financial coverage for RSV prevention, and the authorization of pediatric biological agents.

Anticipated growth during the forecast period is fueled by increasing investments in advanced RSV prevention therapies, a heightened focus on long-acting monoclonal antibodies, the expansion of biologic manufacturing capacity, rising pediatric healthcare expenditure, and the wider adoption of precision immunotherapy approaches. Furthermore, significant trends in this period include the growing embrace of monoclonal antibody-based RSV prophylaxis, an intensifying focus on preventive pediatric immunotherapies, the broadening of cold-chain dependent biologic distribution, an increased emphasis on protecting high-risk infants, and enhanced manufacturing scalability for biologics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20304&type=smp

Which Drivers Are Supporting The Synagis Market Growth?

The increasing occurrence of chronic respiratory conditions is anticipated to stimulate the growth of the synagis market. Chronic respiratory conditions are prolonged ailments that affect the lungs and airways, leading to continuous breathing issues. The prevalence of these conditions can be attributed to several factors, including an aging population, lifestyle choices and smoking, genetic and occupational influences, and environmental pollution. Synagis (palivizumab) works to prevent severe respiratory syncytial virus (RSV) infections in at-risk infants and children, thereby reducing complications and exacerbations in those with chronic respiratory conditions. For instance, in June 2025, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that chronic respiratory diseases impact more than 80 million individuals, with many more undiagnosed, according to a new WHO and European Respiratory Society report. Thus, the rising prevalence of chronic respiratory conditions is driving the expansion of the synagis market.

What Are The Main Segments Within The Synagis Market Segment Structure?

The synagis market covered in this report is segmented –

1) By Clinical Indication: Respiratory Syncytial Virus (RSV) Prophylaxis, Premature Infants With Bronchopulmonary Dysplasia (BPD), Congenital Heart Disease (CHD), Immunocompromised Infants And Children

2) By Formulation: 50 Milligrams (mg)/0.5 Milliliters (mL), 100 Milligrams (mg)/1 Milliliters (mL)

3) By Distribution Channel: Wholesale Distributors, Online Retailers

4) By End-User: Pediatric, Adults

Which Trends Are Shaping The Synagis Market?

Major companies operating in the Synagis market are focusing on obtaining drug approvals to provide preventive therapy for respiratory syncytial virus (RSV), addressing a significant unmet medical need. Drug approval is the regulatory process in which authorities evaluate a drug’s safety, efficacy, and quality based on clinical trial data before authorizing it for use. For instance, in September 2023, AstraZeneca Pharma India Ltd., an India-based biopharmaceutical company, obtained approval from the Central Drugs Standard Control Organisation (CDSCO) to market palivizumab, a preventive therapy for RSV. This injection is available as palivizumab 100 mg/ml in single-dose vials of 50 mg/0.5 ml and 100 mg/ml for intramuscular administration. Palivizumab is indicated for infants born at =35 weeks gestation, children requiring treatment for bronchopulmonary dysplasia (BPD), and those with hemodynamically significant congenital heart disease (CHD). This approval represents the first preventive therapy for RSV available in India.

Who Are The Companies Participating In The Synagis Market?

Major companies operating in the synagis market are Swedish Orphan Biovitrum AB

Get The Full Synagis Market Report:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Which Region Accounts For The Largest Portion Of The Synagis Market?

North America was the largest region in the synagis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the synagis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Synagis Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/synagis-global-market-report

Browse Through More Reports Similar to the Global Synagis Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Vertical Market Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/vertical-market-software-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795